MX2007002682A - Composiciones mejoradas de gamma-hidroxibutirato ghb. - Google Patents

Composiciones mejoradas de gamma-hidroxibutirato ghb.

Info

Publication number
MX2007002682A
MX2007002682A MX2007002682A MX2007002682A MX2007002682A MX 2007002682 A MX2007002682 A MX 2007002682A MX 2007002682 A MX2007002682 A MX 2007002682A MX 2007002682 A MX2007002682 A MX 2007002682A MX 2007002682 A MX2007002682 A MX 2007002682A
Authority
MX
Mexico
Prior art keywords
ghb
improved
ghb compositions
compositions
analog
Prior art date
Application number
MX2007002682A
Other languages
English (en)
Inventor
Mortimer Mamelak
Original Assignee
Orphan Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orphan Medical Inc filed Critical Orphan Medical Inc
Publication of MX2007002682A publication Critical patent/MX2007002682A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invencion proporciona una combinacion de gamma-hidroxibutirato de sodio (GHB) o un profarmaco o un analogo del mismo, con un compuesto que inhibe el metabolismo del GHB o del analogo del GHB in vivo, prolongando de este modo o aumentando la actividad biologica del mismo.
MX2007002682A 2004-09-07 2005-09-07 Composiciones mejoradas de gamma-hidroxibutirato ghb. MX2007002682A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60765104P 2004-09-07 2004-09-07
PCT/US2005/031717 WO2006029155A2 (en) 2004-09-07 2005-09-07 Improved ghb compositions

Publications (1)

Publication Number Publication Date
MX2007002682A true MX2007002682A (es) 2008-03-05

Family

ID=36036948

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007002682A MX2007002682A (es) 2004-09-07 2005-09-07 Composiciones mejoradas de gamma-hidroxibutirato ghb.

Country Status (9)

Country Link
US (1) US20060069040A1 (es)
EP (1) EP1786437A4 (es)
JP (1) JP2008512386A (es)
KR (1) KR20070100686A (es)
AU (1) AU2005282468B2 (es)
BR (1) BRPI0515645A (es)
CA (1) CA2579576A1 (es)
MX (1) MX2007002682A (es)
WO (1) WO2006029155A2 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8771735B2 (en) * 2008-11-04 2014-07-08 Jazz Pharmaceuticals, Inc. Immediate release dosage forms of sodium oxybate
US8778398B2 (en) 2008-11-04 2014-07-15 Jazz Pharmaceuticals, Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
MX2020011961A (es) 2010-03-24 2022-04-19 Jazz Pharmaceuticals Inc Formas de dosis de liberacion controlada para substancias de farmaco de alta dosis, solubles en agua e higroscopicas.
KR20130043198A (ko) 2010-07-16 2013-04-29 피라말 엔터프라이지즈 리미티드 키나제 억제제로서 치환된 이미다조퀴놀린 유도체
US10202623B2 (en) * 2013-01-21 2019-02-12 Sekisui Chemical Co., Ltd. Recombinant cell, and method for producing 1,4-butanediol
DK2968208T3 (da) 2013-03-13 2022-08-22 Jazz Pharmaceuticals Ireland Ltd Behandling af kataplexi
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
CA2999367C (en) 2015-09-23 2023-09-26 Xw Laboratories Inc. Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
US20210369654A1 (en) * 2018-10-16 2021-12-02 Nippon Chemiphar Co., Ltd. Agent for improving quality of sleep
CA3115122A1 (en) 2018-11-19 2020-05-28 Jazz Pharmaceuticals Ireland Limited Alcohol-resistant drug formulations
CN113473980A (zh) 2019-03-01 2021-10-01 弗拉梅尔爱尔兰有限公司 在进食状态下具有改善的药代动力学的γ-羟基丁酸酯组合物
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0235408B1 (en) * 1984-08-06 1991-01-09 The University Of Toronto Innovations Foundation Pharmaceutical composition and treatment
FR2618331B1 (fr) * 1987-07-23 1991-10-04 Synthelabo Compositions pharmaceutiques utiles pour le traitement de l'uremie
FR2754177B1 (fr) * 1996-10-07 1999-08-06 Sanofi Sa Microspheres pharmaceutiques d'acide valproique pour administration orale
US5990162A (en) * 1997-08-29 1999-11-23 Orphan Medical, Inc. Method for treatment of fibromyalgia and chronic fatigue syndrome
WO2000038672A2 (en) * 1998-12-23 2000-07-06 Orphan Medical, Inc. Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
WO2002024715A2 (en) * 2000-09-22 2002-03-28 Orphan Medical, Inc. Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers

Also Published As

Publication number Publication date
JP2008512386A (ja) 2008-04-24
AU2005282468A1 (en) 2006-03-16
BRPI0515645A (pt) 2008-03-04
AU2005282468B2 (en) 2011-04-21
WO2006029155A3 (en) 2007-06-28
WO2006029155A2 (en) 2006-03-16
KR20070100686A (ko) 2007-10-11
EP1786437A2 (en) 2007-05-23
US20060069040A1 (en) 2006-03-30
CA2579576A1 (en) 2006-03-16
EP1786437A4 (en) 2010-12-08

Similar Documents

Publication Publication Date Title
MX2007002682A (es) Composiciones mejoradas de gamma-hidroxibutirato ghb.
SG158175A1 (en) Lipid complexes coated with peg and their use
TW200740369A (en) Pesticidally active compositions having enhanced activity
TW200643453A (en) Polymerizable composition comprising low molecular weight organic component
WO2007062399A3 (en) Oncogenic ras-specific cytotoxic compound and methods of use thereof
TW200613516A (en) Document of value
MX2008001799A (es) Composicion farmaceutica que comprende un inhibidor de dipeptidil peptidasa iv.
MXPA05007328A (es) Composiciones que contienen agentes antiacne y el uso de las mismas.
ECSP034600A (es) Compuestos de lactama
MY184464A (en) Combined use of cholestanol derivative
TW200727920A (en) New regimens for oral monophasic contraceptives
IN2012DN02609A (es)
TW200738283A (en) Formulations of conjugated estrogens and bazedoxifene
JO2578B1 (en) Compounds Theophene benzimidazole
MY133335A (en) Photoresist compositions
ECSP044981A (es) Composicion oftalmica que comprende ascomicina
MY147790A (en) Stable emulsion composition
GT200600379A (es) Composición farmacéutica sólida que comprende 1-(4-cloro-anilino)-4-(4-piridil-metil)-ftalazina y un modificador del ph
WO2006133006A3 (en) 1-methyl-1h-pyrazole-4-carboxamides useful as cancer chemotherapeutic agents
MX2007010990A (es) Agentes endoparasiticidas.
MX2009012370A (es) Formulacion de antraciclina de baja viscosidad.
CO5580729A2 (es) Composiciones nutricionales que comprenden cistationina
EA200600590A1 (ru) Фармацевтические композиции модафинила с модифицированным высвобождением
TNSN07241A1 (en) Substituted pyrroles, compositions containing same, method for making same and use thereof
TW200714596A (en) Isotopically substituted proton pump inhibitors

Legal Events

Date Code Title Description
FG Grant or registration